Ucl Business Plc

Other

Stephen Moss

John Greenwood

Francesca Cordeiro

Xiaomeng Wang

Vineeta Tripathi

Rose Sheridan

Katy Coxon

James Duggan

Maria Francesca Cordeiro

Steven Dakin

Frederick Fitzke

Francesca M Cordeiro

Francesca Maria Cordeiro

The invention provides an antibody or fragment thereof that specifically binds to human Lrg1.

Antibody which binds Lrg1 and methods of use

This invention relates to the field of molecular physiology. Specifically, this invention relates to the treatment of vasculoproliferative conditions, especially those of the eye and in the treatment of tumours that exhibit vascular proliferation. Levels of leucine-rich alpha-2-glycoprotein (Lrg1) have been demonstrated to be increased in patients suffering from such conditions and animal models of such conditions. Antagonists of Lrg1 can be used to treat vasculoproliferative conditions.

Treatment of vasculoproliferative conditions with Lrg1 antagonists

A pharmaceutical composition is provided comprising a vitamin E derivative, an anionic phopholipid-binding protein, an anionic phospholipid and a sterol. Also provided is a method for preparing a composition for delivering a cargo to a subject comprising a) forming liposomes from a vitamin E derivative, an anionic phospholipid-binding protein such as annexin, an anionic phospholipid such as phosphatidylserine and a sterol; and b) encapsulating the cargo in the liposomal composition.

Carrier comprising a vitamin E derivative

The invention relates to a carrier for delivering agents to the posterior region of the eye, the carrier comprising a Vitamin E derivative, especially tocopherol. The carrier may also comprise a cell death marker, such as an annexin.

Pharmaceutical composition comprising a Vitamin E derivative and a cell death marker

The invention relates to methods of diagnosis, particularly methods of staging and diagnosing neurodegenerative diseases using images of cell death in the eye.

Quantifying cell death

This invention relates to the field of molecular physiology. Specifically, this invention relates to treatment of vasculoproliferative conditions, especially those of the eye and in the treatment of tumours that exhibit vascular proliferation. Levels of leucine-rich alpha-2-glycoprotein (Lrg1) have been demonstrated to be increased in patients suffering from such conditions and animal models of such conditions. Antagonists of Lrg1 can be used to treat vasculoproliferative conditions.

Treatment of vasculoproliferative conditions with Lrg1 anatgonists

The invention relates to the use of a cell death marker labelled with a wavelength-optimised label for identifying cell death in the eye. Suitable cell death markers are the Annexins and fragments and derivatives thereof. The invention also relates to a pharmaceutical composition comprising a cell death marker labelled with a wavelength-optimised label and a method for monitoring cell death in the eye using a cell death marker labelled with a wavelength-optimised label.

Growing community of inventors

London, United Kingdom

Stephen Moss